Li Man, Cui Xiaobin, Shen Yaoyuan, Dong Hongchao, Liang Weihua, Chen Yunzhao, Hu Jianming, Li Shugang, Kong Jing, Li Hongan, Zhao Jin, Li Feng
Department of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine, Shihezi 832002, Xinjiang, China; Department of Pathology, The First Affiliated Hospital, Shihezi University School of Medicine, Shihezi 832002, Xinjiang, China.
Department of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine, Shihezi 832002, Xinjiang, China; Department of Pathology, The First Affiliated Hospital, Shihezi University School of Medicine, Shihezi 832002, Xinjiang, China; Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Hum Pathol. 2015 May;46(5):707-15. doi: 10.1016/j.humpath.2015.01.009. Epub 2015 Feb 4.
Oral cancer overexpressed 1 (ORAOV1) has been reported to exhibit high amplification levels in esophageal squamous cell cancer (ESCC) and in premalignant lesions. However, ORAOV1 protein expression levels in ESCC and esophageal squamous intraepithelial neoplasia (ESIN) have not yet been reported. We have explored the relationship of ORAOV1 protein expression with ESCC and ESIN by immunohistochemically analyzing tissue microarrays containing esophageal samples from patients with various clinical features and prognoses. The percentage of ESCC, high-grade ESIN (HGESIN), low-grade ESIN (LGESIN), and nontumoral control patients overexpressing ORAOV1 were 70.63% (101/143), 77.36% (41/53), 48.96% (47/96), and 5.79% (7/121), respectively. ORAOV1 overexpression also appears to be significantly higher in ESCC, HGESIN, and LGESIN than in the controls (all P < .001), and the levels observed for ESCC and HGESIN were also significantly higher than that in LGESIN (both P = .001). These results corresponded to high sensitivity and specificity values in ESCC, HGESIN, and LGESIN tissues. Furthermore, the increased expression of ORAOV1 is significantly associated with lymph node metastasis (P = .001) and an advanced TNM stage (III + IV) (P = .014), and patients with ORAOV1 overexpression experienced shorter overall survival time compared with those with lower ORAOV1 (χ(2) = 11.505, P = .001). This study provides the first evidence of ORAOV1 overexpression in ESCC and ESIN and demonstrates a potential role in tumor progression and metastasis. ORAOV1 overexpression could, therefore, be used as a novel biomarker of poor prognosis in patients with ESCC.
据报道，口腔癌过表达1（ORAOV1）在食管鳞状细胞癌（ESCC）及癌前病变中呈现高扩增水平。然而，ESCC和食管鳞状上皮内瘤变（ESIN）中ORAOV1蛋白表达水平尚未见报道。我们通过免疫组化分析包含具有各种临床特征和预后的患者食管样本的组织芯片，探讨了ORAOV1蛋白表达与ESCC和ESIN的关系。ESCC、高级别ESIN（HGESIN）、低级别ESIN（LGESIN）以及非肿瘤对照患者中ORAOV1过表达的比例分别为70.63%（101/143）、77.36%（41/53）、48.96%（47/96）和5.79%（7/121）。ORAOV1过表达在ESCC、HGESIN和LGESIN中也似乎显著高于对照组（所有P <.001），并且ESCC和HGESIN中观察到的水平也显著高于LGESIN（两者P =.001）。这些结果与ESCC、HGESIN和LGESIN组织中的高灵敏度和特异性值相符。此外，ORAOV1表达增加与淋巴结转移（P =.001）和晚期TNM分期（III + IV）（P =.014）显著相关，与ORAOV1表达较低的患者相比，ORAOV过表达的患者总生存时间较短（χ(2)= 11.505，P =.001）。本研究提供了ESCC和ESIN中ORAOV1过表达的首个证据，并证明其在肿瘤进展和转移中的潜在作用。因此，ORAOV1过表达可作为ESCC患者预后不良的一种新型生物标志物。
Zotero 插件